Non-insulin pharmacological agents use different glucose-lowering mechanisms and can be used as monotherapy or in combination, while insulin provides the default medicine for the most advanced stages of this progressive disease [2,3,4]
Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial
Induced human regulatory t cells express the glucagon-like peptide-1 receptor
Clinical Study Results (SURMOUNT & SURPASS) Tirzepatide has been evaluated in large phase 3 clinical studies in humans: Weight reduction: In the SURMOUNT studies, participants achieved up to 20.9% mean body-weight loss at the highest dose
Most patients take semaglutide once weekly under medical supervision
A high-protein, nutrient-dense diet (preserves muscle, improves energy)